:
. . . . / . : http://www.who.int/immunization/documents/positionpapers/en/index.html.
. .
.
.
1
O1)
. .
.
. . .
.
(O139
. . / , . .(
/ , / ,
/ ,
.
/ , ) .O1 . .
. .
. . . O1
.
/
.
، ،
.
Deen JL et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Neglected Tropical Diseases, 2008, 2(2):e173. See No 31, 2009, pp. 309–324. Zuckerman JN et al. The true burden and risk of cholera: implications for prevention and control. Lancet Infectious Diseases, 2007, 7:521–530 Tacket CO et al. Cholera vaccines. In: Plotkin SA, Orenstein WA, Offit P, eds. Vaccines, 7thed. Philadelphia, PA, WB Saunders Company, 2008:127–138 2
.
. O139 O1
.(O) . : O1
. .
. (O139 .O1 . . ، .
.
. .
) O139
. O139
O139
. GM-1
. B
O139
.
.
.GM-1
O1 A
(
.
) .
The treatment of diarrohea: a manual for physicians and other senior health workers. Geneva, World Health Organization, 2005 (WHO/CDD/SER/80.2). Schwartz BS et al. Diarrheal epidemics in Dhaka, Bangladesh, during three consecutive floods: 1988, 1998 and 2004. American Journal of Tropical Medicine and Hygiene, 2006, 74:1067–1073 Nair GB et al. Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. Journal of Clinical Microbiology, 2006, 44:4211–4213 Ansaruzzaman M et al. Genetic diversity of El Tor strains of Vibrio cholera O1with hybrid traits isolated from Bangladesh and Mozambique. International Journal of Medical Microbiology, 2007, 297:443–449 Siddique AK et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiology and Infection, 2009, 14:1–6 Sack DA et al. Antimicrobial resistance in shigellosis, cholera and campylobacteriosis. Geneva, World Health Organization, 2001 (WHO/CDS/SCR/DRS/2001.8). 3
. O
. . . . .
. .( . ) )
.( . .
( ) (Dukoral)
( ): .( )
.(mORCVAX)
(Shanshol)
.
.
.(CVD
103-HgR)
(WC-rBS) . O1 B
.
.
) . (
(WC) . rBS BS
B
.(WC-rBS) .( B
( ) .
) .
Sack DA et al. Cholera. Lancet, 2004, 363:223–233. Background paper on the integration of oral cholera vaccines into global cholera control programmes presented to the WHO SAGE in October 2009 [draft document]. Geneva, Ad-hoc vaccine working grou (http:www.who.int/entity/immunization/sage/1_Background_Paper_Cholera_Vaccines_FINALdraft_13_oct_v2.pdf; acces-sed March 2010). 4
)
. . .
(
) .( .
.
. .
.
.
.
. . . .
.
.
A
. ( ( ) WC-BS
.
(
) (
.
)
)
) . ( .
Holmgren J et al. Oral B-subunit killed whole-cell cholera vaccine. In: Levine MM et al, eds. New generation vaccines, 3rd ed. New York, Marcel Dekker, 2004:991–1014. 5
( .
)
) ( .
( ) WC-BS
(
) . (
. )
،
.
. .
. . ) ) . ) . (
)
(
.(
(
. ( ( ) ( ) )
Clemens JD et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet, 1990, 335:270–273 Van Loon FPL et al. Field trial of inactivated cholera vaccines in Bangladesh: results from 5 years of followup. Vaccine, 1996, 14:162–166. Clemens JD et al. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet, 1988, 331:1375–1379. Sanchez JL et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet, 1994, 344:1273–1276. Clemens JD et al. Misleading negative findings in a field trial of killed, oral cholera vaccine in Peru. Journal of Infectious Diseases, 2001,183:1306–1308. Taylor DN et al. Two-year study of the protective efficacy of the oral whole-cell plus recombinant B subunit cholera vaccine in Peru. Journal of Infectious Diseases, 2000; 181:1667–1673. Lucas ME et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. New England Journal of Medicine, 2005, 352:757–767. Most of those in the group classified as receiving 1 or 2 doses had actually received 2 doses, hence they had a similar level of protection as those in the group that received 2 doses. 6
.
O1
.
.
. . .
. (mORCVAX) . .O139 O1 B
(Shanshol)
.
.
(mORCVAX) . .
. . . (mORCVAX) ).
.
.( .
.
Peltola H et al. Prevention of travellers’ diarrhoea by oral B- subunit/whole-cell cholera vaccine. Lancet, 1991, 338:1285–1289. Hill DR et al. Oral cholera vaccines: use in clinical practice. Lancet Infectious Diseases, 2007, 7:361–373. Guidelines for the production and control of inactivated oral cholera vaccines. Geneva, World Health Organization, 2004 (WHO Technical report series 924 (Annex 3). (Also available from http://www.who.int/biologicals/publications/trs/areas/vaccines/cholera/en/index.html.) 7
. WC
.
) )
" "
. ( . . .(
.O139 .( ) .
O139 O1
. .
. (
. . .
.
)
Anh DD et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine, 2007, 25:1149–1155. Mahalanabis D et al. A randomized, placebo controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One, 2008, 3(6):e2323. Trach DD et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet, 1997, 349:231–235. Thiem VD et.al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine, 2006, 24:4297–4303.
:
.(
: )
. : .(
( .( .(
) ) ) )
. )
http://www.who.int/immunization/cholera_grad_safety.pdf http://www.who.int/immunization/cholera_grad_effectiveness.pdf
: http://www.who.int/immunizatio/cholerq_grad_safety.pdf
:
: 8
.(
.
. B
WC-rBS WC
. /
/ , . . .
WC
.
. . . .(the Diseases , ) ) . of the Most Impoverished Program)
( , . .( (
.
)
,
Ali M et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet, 2005, 366:44– 49. Longini IM et al. Controlling endemic cholera with oral vaccines. PLoS Medicine, 2007, 4(11):e336. Sack DA. Herd protection and herd amplification in cholera. Journal of Health, Population and Nutrition, 2006, 24(1):1–5. Jeuland M et al. Cost-effectiveness of new-generation oral cholera vaccines: a multi-site analysis. Value in Health, 2009, 12:899–908. 9
.
.
. . .
. .( ) ( .( )
)
.
.
."
"
:
. . . . .
. .
.
.
See No. 50, 2009, pp. 517–532. 10
.
( ) ( ) .
( )
. ( )
.
. (
. . .
)
.
Oral cholera vaccine use in complex emergencies: what next? Geneva, World Health Organization, 2001 (WHO/CDS/NTD/IDM/2006.2). (Also available from http://www.who.int/cholera/publications/cholera_vaccines_emergencies_2005.pdf.) See Annex 1 of reference 37 above. 11
/
/
/
O1
.
/
–
|
12
/
O139 O1
.
.
:
O1
. . . . . ) .
/
–
|
/ * . . . :(WC-rBS) (WC) : .O139 ( ( O1
B
O1
:CVD 103-HgR * .
/
–
|
13
/
( (
:
) ) . . . .
.
:
.
: .
/ .
/
–
|
/
/ ) : ( / / . /
/
–
|
14
/
(
)
( B
)
/ . / / B
/
/
–
|
/
.
. . ( ) .
.(
)
/
–
|
15
/
.( . .
).
.
.
. .
/
–
|
/
. .
.
.
.
/
–
|
16
/
.
/
–
|
17
/ .
. . /
. . . O139
.
O1
. O1
. . O1
∗.
.B
.( .(
B
). O1
B
O139
)
. .
.
" " . .
.
. . . /
.
. B
.
.
. . . . 18
:CVD
103-HgR
∗